[A newly established melanoma cell line (GAK) with 5-S-cysteinyldopa phenotype]. 1984

S Nozawa, and H Ohta, and K Tsukazaki, and Y Udagawa, and S Kurihara, and S Kano

The production of 5-S-cysteinyldopa by a newly established melanoma cell line GAK is reported. The cell line was derived from a metastatic inguinal lymph node of vulvar malignant melanoma. The cell line grew well without interruption for over 4 years, GAK cells were proved to have melanin granules and tyrosinase activity in their cytoplasma by Masson's staining and dopa reaction, respectively. Melanin granules were ultrastructually identified as melanosomes in various maturing stages. The chromosomal number varied widely and showed aneuploidly, but the modal chromosomal number was stable in the hypotriploid range. GAK cells were transplanted to nude mice and produced tumors resembling the original. Because glucose-6-phosphate dehydrogenase of GAK revealed a type B (slow) mobility pattern on electrophoresis, the possibility of Hela cell contamination could be completely excluded. High performance liquid chromatography revealed "5-S-cysteinyldopa", a new tumor marker of malignant melanoma, in culture media of GAK cells. The cell line described may serve as a representative model system for basic and clinical studies on malignant melanoma.

UI MeSH Term Description Entries
D007536 Isomerism The phenomenon whereby certain chemical compounds have structures that are different although the compounds possess the same elemental composition. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Isomerisms
D008207 Lymphatic Metastasis Transfer of a neoplasm from its primary site to lymph nodes or to distant parts of the body by way of the lymphatic system. Lymph Node Metastasis,Lymph Node Metastases,Lymphatic Metastases,Metastasis, Lymph Node
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D008819 Mice, Nude Mutant mice homozygous for the recessive gene "nude" which fail to develop a thymus. They are useful in tumor studies and studies on immune responses. Athymic Mice,Mice, Athymic,Nude Mice,Mouse, Athymic,Mouse, Nude,Athymic Mouse,Nude Mouse
D009368 Neoplasm Transplantation Experimental transplantation of neoplasms in laboratory animals for research purposes. Transplantation, Neoplasm,Neoplasm Transplantations,Transplantations, Neoplasm
D010641 Phenotype The outward appearance of the individual. It is the product of interactions between genes, and between the GENOTYPE and the environment. Phenotypes
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D003548 Cysteinyldopa Found in large amounts in the plasma and urine of patients with malignant melanoma. It is therefore used in the diagnosis of melanoma and for the detection of postoperative metastases. Cysteinyldopa is believed to be formed by the rapid enzymatic hydrolysis of 5-S-glutathionedopa found in melanin-producing cells. 5-S-Cysteinyldopa,5 S Cysteinyldopa
D004295 Dihydroxyphenylalanine A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific. Dopa,3,4-Dihydroxyphenylalanine,3-Hydroxy-DL-tyrosine,Dihydroxyphenylalanine Hydrochloride, (2:1),beta-Hydroxytyrosine,3 Hydroxy DL tyrosine,3,4 Dihydroxyphenylalanine,beta Hydroxytyrosine
D005260 Female Females

Related Publications

S Nozawa, and H Ohta, and K Tsukazaki, and Y Udagawa, and S Kurihara, and S Kano
November 1992, The Journal of dermatology,
S Nozawa, and H Ohta, and K Tsukazaki, and Y Udagawa, and S Kurihara, and S Kano
October 2000, European journal of clinical investigation,
S Nozawa, and H Ohta, and K Tsukazaki, and Y Udagawa, and S Kurihara, and S Kano
January 1979, Acta dermato-venereologica,
S Nozawa, and H Ohta, and K Tsukazaki, and Y Udagawa, and S Kurihara, and S Kano
January 2020, International journal of molecular sciences,
S Nozawa, and H Ohta, and K Tsukazaki, and Y Udagawa, and S Kurihara, and S Kano
January 1977, Acta dermato-venereologica,
S Nozawa, and H Ohta, and K Tsukazaki, and Y Udagawa, and S Kurihara, and S Kano
January 1975, Acta dermato-venereologica,
S Nozawa, and H Ohta, and K Tsukazaki, and Y Udagawa, and S Kurihara, and S Kano
January 2002, Neoplasma,
S Nozawa, and H Ohta, and K Tsukazaki, and Y Udagawa, and S Kurihara, and S Kano
November 1975, La Revue du praticien,
S Nozawa, and H Ohta, and K Tsukazaki, and Y Udagawa, and S Kurihara, and S Kano
February 1988, The Journal of investigative dermatology,
S Nozawa, and H Ohta, and K Tsukazaki, and Y Udagawa, and S Kurihara, and S Kano
May 1998, Nippon Ganka Gakkai zasshi,
Copied contents to your clipboard!